Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab safety and lipid-lowering study in high cardiovascular risk patients with severe hypercholesterolemia
2015-000620-28Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Primary endpoint: Proportion of patients with adverse events. Started May 2015; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2015-000620-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000620-28.